Austin, TX 10/18/2007 10:53:34 PM
Speak with other shareholders about: (OTC BB:PVCT) , (Nasdaq:CACH) , (OTC BB:SKNY) , (NYSE:BSX)
AUSTIN, TX: October 18, 2007 – Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the “Chat Live” button at the top.
----------------------------------------------------------
Chat real-time with other investors about this PVCT news release, by
clicking this link: http://www.stockwire.com/PVCT
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=PVCT
Provectus Pharmaceuticals, Inc (OTC BB:PVCT) Current Price (2.20) KNOXVILLE, Tenn.--Oct 17--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT - News) announced today it has received allowance of its U.S. patent application, protecting diagnostic uses of a new class of radiochemical agents related to its therapeutic product PV-10, from the United States Patent and Trademark Office (USPTO). Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies that are safer, more effective and less invasive than conventional therapies. Provectus is currently conducting clinical trials of their proprietary drugs Provecta(TM) (PV-10) as a therapy for melanoma and breast cancer, as well as Xantryl(TM), a topical treatment for severe psoriasis and eczema. Further, use of Provecta for melanoma has received orphan drug designation from the FDA. Additionally, the company is about to begin Phase 2 of clinical testing for Xantryl for psoriasis. For additional information about Provectus please visit the company's website at www.pvct.com or contact The Investor Relations Group via the information provided below.
----------------------------------------------------------
Chat real-time with other investors about this CACH news release, by
clicking this link: http://www.stockwire.com/CACH
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=CACH
Cache Inc., (Nasdaq:CACH) Current Price (16.75) NEW YORK--Oct 17--Cache Inc., (NASDAQ: CACH - News) today announced that the Company will conduct a conference call to discuss third quarter 2007 results. The call, scheduled for Wednesday, October 24, 2007 at 9:00 a.m. Eastern Time, will be hosted by Brian Woolf, Chairman and Chief Executive Officer, Thomas Reinckens, President and Chief Operating Officer and Maggie Feeney, Executive Vice President and Chief Financial Officer. Cache is a nationwide, mall-based specialty retailer of sophisticated, social occasion sportswear and dresses targeting style-conscious women. Cache targets women between the ages of 25 and 45 who have a youthful attitude, are self-confident and fashion-conscious, and require a missy fit. We operate 296 Cache and Cache Luxe stores primarily situated in central locations in high traffic, upscale malls in 44 states, the Virgin Islands and Puerto Rico.
----------------------------------------------------------
Chat real-time with other investors about this SKNY news release, by
clicking this link: http://www.stockwire.com/SKNY
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=SKNY
Skinny Nutritional Corp.
(OTC BB:SKNY) Current Price (0.12) BALA CYNWYD, Pa.--Oct 16--Skinny Nutritional Corporation (OTC:BB SKNY.OB) announced today that the company is more than doubling its distribution of Skinny Water , an appetite-suppressing flavored fitness water, with a major retailer. Skinny Water is now available in an additional 539 stores with a concentration of stores on the East Coast from Florida to Maine, starting around November 20, 2007. This follows Skinny Water's successful September expansion into 408 stores nationwide, and brings the total number of stores carrying Skinny Water to 947. The retailer will sell Skinny Water's newest flavor, peach, in addition to two other fruit flavors, raspberry and lemon. Skinny Nutritional develops, acquires, and distributes lifestyle and consumer products that capital on emerging trends in the health and wellness industry. Headquartered in Bala Cynwyd, Pa., the company is the exclusive worldwide distributor of Skinny Water , Skinny Snacks(TM), and Nicogel, a cigarette replacement hand gel. For more information, visit www.skinnyco.com.
----------------------------------------------------------
Chat real-time with other investors about this BSX news release, by
clicking this link: http://www.stockwire.com/BSX
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=BSX
Boston Scientific Corporation (NYSE:BSX) Current Price (14.14) NATICK, Mass., Oct. 17 -- Boston Scientific Corporation (NYSE: BSX - News) today announced several new initiatives designed to enhance short- and long-term shareholder value, including the restructuring or sale of several business units, as well as substantial expense and head count reductions intended to bring expenses in line with revenues. The Company also said it is making good progress toward the execution of its previously announced plans to sell non-strategic assets and monetize the majority of its public and private investment portfolio. The Company said these initiatives will help provide better focus on core businesses and priorities, which will strengthen Boston Scientific for the future and lead to increased, sustainable and profitable sales growth. Boston Scientific Corporation engages in the development, manufacture, and marketing of medical devices that are used in interventional medical specialties worldwide. The company offers its products in three groups: Cardiovascular, Endosurgery, and Neuromodulation. The Cardiovascular group focuses on products and technologies for use in interventional cardiology, cardiac rhythm management, peripheral interventions, cardiac surgery, vascular surgery, electrophysiology, and neurovascular procedures. The Endosurgery group offers products that are used in helping patients with malignant and benign tumors, gastrointestinal cancers, incontinence, abscesses, end stage renal disease, benign prostatic hyperplasia, gallstones, and urinary stone disease, as well as uterine fibroids and menorrhagia. The Neuromodulation group provides auditory solutions to treat permanent deafness through the use of cochlear implants; and pain management devices that use neurostimulation to mask chronic pain signals with electrical impulses. The company's medical products are used for enlarging narrowed blood vessels to prevent heart attack and stroke; clearing passages blocked by plaque to restore blood flow; detecting and managing fast, slow, or irregular heart rhythms; mapping electrical problems in the heart; opening obstructions and bringing relief to patients suffering from various forms of cancer; performing biopsies and intravascular ultrasounds; placing filters to prevent blood clots from reaching the lungs, heart, or brain; treating urological, gynecological, renal, pulmonary, neurovascular, and gastrointestinal diseases; and modulating nerve activity to treat deafness and chronic pain. It markets its products through direct sales force, and a network of distributors and dealers. Boston Scientific Corporation has a strategic collaboration with CryoCor, Inc. for the treatment of cardiac arrhythmias. The company was founded in 1979 and is headquartered in Natick, Massachusetts.
----------------------------------------------------------
As a trader, a very intelligent place to put your money, is where the money is flowing into. These are the kind of trades that you want to get into.
As the saying goes...follow the money!
To see the complete Movers & Shakers Blog go to: http://www.stockwire.com .
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE RESEARCH GROUP INC..
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com, which is owned by Stockwire Research Group Inc. (SRGI). To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company on Stockwire.com is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. We intend to sell these shares at any given time.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
